Search

everythinglearnresearchcommunity

for

Search:↓

ISCK03 stops melanin production in human melanoma cells and lightens skin color in mice and guinea pigs.

Topical JAK inhibitors may help treat some skin conditions but need more research.

Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.

Topical tofacitinib may help regrow hair in children with alopecia totalis.

Targeting JAK-STAT1 can reduce inflammation and promote hair growth in conditions linked to EGFR deficiency.

Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.

A man's hair regrew from alopecia areata after using tofacitinib and experiencing contact dermatitis from a wig device.

Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.

Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.

Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.

Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.

Hair samples can reliably monitor tacrolimus levels in kidney transplant patients.

Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.

Tofacitinib may help treat severe hair loss, but more research is needed.

Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.

JAK inhibitors show promise for treating alopecia areata but their effectiveness and safety are still debated.

JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.

Tedisamil and glibenclamide affect cromakalim and minoxidil sulphate differently in rat aorta.

Baricitinib successfully regrew hair in an 8-year-old boy with alopecia totalis linked to a KRT74 gene variant.

Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.

ICI therapy increases the risk of gastrointestinal and endocrine issues in psoriasis patients.

Tofacitinib helped a woman with total-body hair loss grow her hair back.

ZD1839 (Iressa) causes skin and hair side effects, treatable with tretinoin cream and minocycline.

A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.

Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.

Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.